Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia

Bibliography

• Fratiglioni L, Launer LJ, Andersen K, Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S10-5
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56:730-6
   PubMed Web of Science ®Google Scholar
• Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988;1:24-36
   PubMedGoogle Scholar
• Nitti VW, Sanders S, Staskin DR, Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 2006;67:657-64
   PubMed Web of Science ®Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403
   PubMed Web of Science ®Google Scholar
• Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999;12:307-23
   Web of Science ®Google Scholar
• Darreh-Shori T, Almkvist O, Guan ZZ, Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-72
   PubMed Web of Science ®Google Scholar
• Lane R, He Y. Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ϵ4, and hyperhomocysteinemia in neurodegenerative dementias. Med Hypotheses 2009;73:230-50
   PubMed Web of Science ®Google Scholar
• Lane R, Feldman HH, Meyer J, Synergistic effect of apolipoprotein E ϵ4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 2008;18:289-98
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Modiri N, Nordberg A. ApoE and amyloid beta deflate the cholinergic transmission by boosting the activity and stability of cholinesterases in the brain. Poster presented at the International Conference on Alzheimer's Disease (ICAD), Vienna, Austria, 2009
   Google Scholar
• Darreh-Shori T, Modiri N, Nordberg A. Apolipoprotein E and butyrylcholinesterase synergistically promote Ab peptides oligomerization. Poster presented at the International Conference on Alzheimer's Disease (ICAD), Vienna, Austria, 2009
   Google Scholar
• Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-39
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Sędek G, Jhee S, Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008;83:106-14
   PubMed Web of Science ®Google Scholar
• Mercier F, Lefèvre G, Huang HL, Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007;23:3199-204
   PubMed Web of Science ®Google Scholar
• Rivastigmine (Exelon®) summary of product characteristics. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Exelon/H-169-PI-en.pdf [Last accessed 15 July 2009]
   Google Scholar
• Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996;8:109-16
   Google Scholar
• Lefévre G, Sędek G, Huang HL, Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007;47:471-8
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
   Google Scholar
• Rösler M, Anand R, Cicin-Sain A, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8
   PubMed Web of Science ®Google Scholar
• Feldman HH, Lane R. Rivastigmine: a placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007;78:1056-63
   PubMed Web of Science ®Google Scholar
• Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:S26-34
   Google Scholar
• Emre M, Aarsland D, Albanese A, Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N, A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Suh GH, Wimo A, Gauthier S, International price comparisons of Alzheimer's drugs: a way to close the affordability gap. Int Psychogeriatr 2009;21:1-11
   Google Scholar
• Loveman E, Green C, Kirby J, The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10:1-160
   Web of Science ®Google Scholar
• Mucha L, Shaohung S, Cuffel B, Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm 2008;14:451-61
   PubMed Web of Science ®Google Scholar
• Nagy B, Brennan A, Brandtmuller A, The cost-utility of the rivastigmine transdermal patch in the management of patients with moderate Alzheimer's disease in the US. Poster presented at the annual meeting of the American Association for Geriatric Psychiatry (AAGP), Orlando, Florida, USA, 14–17 March, 2008
   Google Scholar
• Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002:45-63
   Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009:CD001191
   Google Scholar
• Kurz A, Farlow M, Lefevre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 2009;63:799-805
   PubMed Web of Science ®Google Scholar
• Sadowsky C, Cummings J, Tekin S, Lane R. Achieving optimal therapeutic doses – rivastigmine (Exelon) patch and capsule. Poster presented at the 132nd Annual Meeting of the American Neurological Association (ANA), Washington, DC, USA, 7–10 October, 2007
   Google Scholar
• Venkatesh K, Bullock R, Akbas A. Strategies to improve tolerability of rivastigmine: a case series. Curr Med Res Opin 2007;23:93-5
   PubMed Web of Science ®Google Scholar
• Grossberg G, Sadowsky C, Förstl H, Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009;23:158-64
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M, Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456-61
   PubMed Web of Science ®Google Scholar
• Farlow M, Anand R, Messina J Jr, A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-41
   PubMed Web of Science ®Google Scholar
• Widman TJ, Oostman H, Storrs FJ. Allergic contact dermatitis from medical adhesive bandages in patients who report having a reaction to medical bandages. Dermatitis 2008;19:32-7
   PubMed Web of Science ®Google Scholar
• Levin C, Maibach HI. Transdermal drug delivery system: an overview. In: Zhai, H Maibach, H editors, Marzulli and Maibach's Dermatotoxicology, 6th edition; Boca Raton, FL, 2008:101-6
   Google Scholar
• Swinn L, Schrag A, Viswanathan R, Sweating dysfunction in Parkinson's disease. Mov Disord 2003;18:1459-63
   PubMed Web of Science ®Google Scholar
• Taylor P. Anticholinesterase agents. In: Goodman, AG Rall, TW Nies, ASTaylor, P editors, Goodman and Gilman's: The pharmacological basis of therapeutics, 8th edition; 1990
   Google Scholar
• Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002;42:558-68
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 2004;63:1093-95
   PubMed Web of Science ®Google Scholar
• Ballard C, Lane R, Barone P, Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006;60:639-45
   PubMed Web of Science ®Google Scholar
• Oertel W, Poewe W, Wolters E, Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf 2008;31:79-94
   PubMed Web of Science ®Google Scholar
• Lee J-H. Effects of body weight on tolerability of rivastigmine transdermal patch. Poster presented at the 24th Conference of Alzheimer's Disease International (ADI), Singapore, 2009
   Google Scholar
• Lèfevre G, Buche M, Sèdek G, Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol 2009;49:430-43
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Stahelin HB, Messina JC, Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000;15:242-47
   PubMed Web of Science ®Google Scholar
• Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998;13:391-411
   PubMed Web of Science ®Google Scholar
• Winblad B, Kawata AK, Beusterien KM, Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:485-91
   PubMed Web of Science ®Google Scholar
• Giacobini E, Spiegel R, Enz A, Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053-65
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Modiri N, Blennow K, The apolipoprotein E varepsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging 2009: published online August 27, doi:10.1016/j.neurobiolaging.2009.07.015
   Google Scholar
• Diamant S, Podoly E, Friedler A, Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006;103:8628-33
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Alvarez A, Garrido J, Acetylcholinesterase promotes Alzheimer b-amyloid fibil formation. In: Iqbal K, Winblad B, Nishimura T, , editors, Alzheimer's disease: biology, diagnosis and therapeutics. John Wiley & Sons Ltd; 1997
   Google Scholar
• Donepezil (Aricept®) summary of product characteristics. Available from: http://emc.medicines.org.uk/medicine/577/SPC/Aricept [Last accessed 9 October 2009]
   Google Scholar
• Galantamine (Razadyne ER®) prescribing information. Available from: https://www.ortho-mcneilneurologics.com/ortho-mcneilneurologics/shared/pi/razadyne_er.pdf [Last accessed 9 October 2009]
   Google Scholar